
MSD to Acquire Verona Pharma for $10 Billion
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.
MSD (Merck & Co.) and Hengrui Pharma recently announced that they have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor.
Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.
Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include MSD’s MK-6070, a compound MSD obtained through its recent acquisition of Harpoon Therapeutics.
US drugmaker Merck & Co. (MSD) has agreed to acquire privately held ophthalmology-focused biotechnology company Eyebiotech (EyeBio).
US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity value of $680 million.
In Ireland, US drugmaker MSD has opened its new facility in Dunboyne, County Meath, and has expanded its Carlow site. MSD says it has invested more than €1 billion at both sites, creating 670 new jobs and increasing the number of employees in Ireland to 3,100. 100 of the newly created positions remain to be filled.
UK-based Astex Pharmaceuticals, specialized in the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced an exclusive worldwide research collaboration and license agreement with US drugmaker MSD (in the US, the company trades as Merck & Co).
Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
US drugs giant Merck & Co has granted Sinopharm exclusive import and distribution rights to its oral Covid treatment Lagevrio (molnupiravir) in China.
US pharma giant Merck & Co has applied to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its oral antiviral drug molnupiravir, developed together with Ridgeback Biotherapeutics. The New Jersey-based pharma and the Florida-headquartered biotech are positioning the pill as a preventative therapy, rather than as a therapeutic, the latter a path other industry heavyweights are taking.
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.
Another “Big Pharma” company with a stalled candidate of its own is stepping in to help boost national or regional Covid-19 vaccine supply. US president Joe Biden was due to announce on Mar. 2 that Merck & Co will help make the Johnson & Johnson single-shot vaccine that received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on Feb. 27.
US pharma giant Merck has divested its direct holding in Moderna just as the US biotech is on the cusp of receiving an emergency use authorization (EUA) for its mRNA-based Covid-19. It said it expects to “record a small fourth-quarter gain.”